<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82676">
  <stage>Registered</stage>
  <submitdate>18/03/2008</submitdate>
  <approvaldate>31/03/2008</approvaldate>
  <actrnumber>ACTRN12608000153314</actrnumber>
  <trial_identification>
    <studytitle>Investigation of the role of tumour-associated macrophages in the development and progression of lung cancer</studytitle>
    <scientifictitle>Investigation of the role of tumour-associated macrophages in the development and progression of lung cancer</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Lung cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Bronchoalveolar lavage (BAL) of lung of patients undergoing bronchoscopy for suspected lung cancer / Lung resected for management of known lung cancer. BAL involves installation of a small amount of saline into the lung, via the bronchoscope, then removing the fluid via suctino to allow diagnosis of cells retrieved within the fluid. This is a standard diagnostic procedure in bronchoscopy. 
 Analysis of the behaviour of inflammatory cells in lung cancer, specifically, the role tumour-associated lung cancer play in the progression of lung cancer. 
We hope to determine the diagnostic and prognostic value of such information</interventions>
    <comparator>Bronchoalveolar lavage (BAL) or wedge resection of adjacent lobe (for BAL) or non-tumour-bearing lung (for post-surgical specimens) to attain a "control" specimen</comparator>
    <control>Active</control>
    <interventioncode>Early detection / Screening</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Sensitivity and specificity will be determined following analysis of both cell surface markers of alveolar macrophages, as well as characteristics (eg. phagocytic ability, inducible proteins). The ability of these to determine the diagnosis of cancer will be compared to the gold standard of histologic analysis of surgically resected specimen. Sensitivity (ability to detect a condition if it is present)/Specificity (how specific a positive result is for the particular condition being studied) of analysis of BAL inflammatory cells in determining the diagnosis of peripheral lung lesions.</outcome>
      <timepoint>36 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Prognositc value of the presence/density/behaviour characteristics of inflammatory - ie. can information obtained from analysis predict whether patients will experience higher or lower rates of disease recurrence after surgery, or longer or shorter survival times following their diagnosis of lung cancer.</outcome>
      <timepoint>36 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>BAL - suspected lung cancer on the basis of radiologic imaging
Resection - known lung cancer, undergoing lung resection as treatment for known lung cancer</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>N/A</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Known diagnosis of lung cancer
medical condition precludes bronchoscopy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/05/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Melbourne Hospital</primarysponsorname>
    <primarysponsoraddress>Grattan St
Melbourne Victoria 3050 </primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health &amp; Medical Research Council</fundingname>
      <fundingaddress>GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>31/03/2008</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Daniel Steinfort</name>
      <address>c/- Department of Respiratory Medicine
Royal Melbourne Hospital
Grattan St
Melbourne Victoria 3050</address>
      <phone>+61 3 93427708</phone>
      <fax />
      <email>daniel.steinfort@mh.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Daniel Steinfort</name>
      <address>c/- Department of Respiratory Medicine
Royal Melbourne Hospital
Grattan St
Melbourne Victoria 3050</address>
      <phone>+61 3 93427708</phone>
      <fax />
      <email>daniel.steinfort@mh.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>